1. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. (31st March 2020) Authors: Barok, Mark; Le Joncour, Vadim; Martins, Ana; Isola, Jorma; Salmikangas, Marko; Laakkonen, Pirjo; Joensuu, Heikki Journal: Cancer letters Issue: Volume 473(2020) Page Start: 156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer. Issue 3 (March 2018) Authors: Luhtala, Satu; Staff, Synnöve; Barok, Mark; Tanner, Minna; Isola, Jorma Journal: Applied immunohistochemistry & molecular morphology Issue: Volume 26:Issue 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy. Issue 4 (13th February 2021) Authors: Barok, Mark; Puhka, Maija; Yazdi, Narjes; Joensuu, Heikki Journal: Journal of extracellular vesicles Issue: Volume 10:Issue 4(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗